Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.
paper
Cited
Public
Unavailable
- Authors
- Panlilio, Leigh V; Justinova, Zuzana; Mascia, Paola; Pistis, Marco; Luchicchi, Antonio; Lecca, Salvatore; Barnes, Chanel; Redhi, Godfrey H; Adair, Jordan; Heishman, Stephen J; Yasar, Sevil; Aliczki, Mano; Haller, Jozsef; Goldberg, Steven R
- Year
- 2012
- Journal
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
- PMID
- 22453137
- DOI
- 10.1038/npp.2012.31
- PMCID
- PMC3376316
Experimental drugs that activate Ξ±-type peroxisome proliferator-activated receptors (PPARΞ±) have recently been shown to reduce the rewarding effects of nicotine in animals, but these drugs have not been approved for human use. The fibrates are a class of PPARΞ±-activating medications that are widely prescribed to improve lipid profiles and prevent cardiovascular disease, but these drugs have not been tested in animal models of nicotine reward. Here, we examine the effects of clofibrate, a representative of the fibrate class, on reward-related behavioral, electrophysiological, and neurochemical effects of nicotine in rats and squirrel monkeys. Clofibrate prevented the acquisition of nicotine-taking behavior in naive animals, substantially decreased nicotine taking in experienced animals, and counteracted the relapse-inducing effects of re-exposure to nicotine or nicotine-associated cues after a period of abstinence. In the central nervous system, clofibrate blocked nicotine's effects on neuronal firing in the ventral tegmental area and on dopamine release in the nucleus accumbens shell. All of these results suggest that fibrate medications might promote smoking cessation. The fact that fibrates are already approved for human use could expedite clinical trials and subsequent implementation of fibrates as a treatment for tobacco dependence, especially in smokers with abnormal lipid profiles.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Cannabinoid-based Pharmacology for the Management of Substance Use Disorders. | LujΓ‘n MΓ et al. | β | 2026 | β |
| Cholesterol modulation of interactions between psychostimulants and dopamine transporters. | Chen R | β | 2024 | β |
| Molecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives. | Badshah I et al. | β | 2024 | β |
| Nicotinic regulation of microglia: potential contributions to addiction. | Soares AR et al. | β | 2024 | β |
| New medications development for smoking cessation. | Lengel D et al. | β | 2023 | β |
| The 2022 Ferno Award Address: CrEATE, an Efficient Crossover Evaluation of Addiction Treatment Efficacy. | Perkins KA | β | 2023 | β |
| Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies. | Jung T et al. | β | 2022 | β |
| Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement. | LujΓ‘n MΓ et al. | β | 2021 | β |
| PPARΞ± Modulation-Based Therapy in Central Nervous System Diseases. | Lee D et al. | β | 2021 | β |
| Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. | Sagheddu C et al. | β | 2021 | β |
| Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. | Smith LC et al. | β | 2020 | β |
| Norfluoxetine and venlafaxine in zebrafish larvae: Single and combined toxicity of two pharmaceutical products relevant for risk assessment. | Rodrigues P et al. | β | 2020 | β |
| PPAR-Mediated Toxicology and Applied Pharmacology. | Xi Y et al. | β | 2020 | β |
| Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. | Matheson J et al. | β | 2020 | β |
| Enhancement of fear learning in PPARΞ± knockout mice. | Chikahisa S et al. | β | 2019 | β |
| Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. | Sagheddu C et al. | β | 2019 | β |
| Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse. | Schmidt HD et al. | β | 2019 | β |
| N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. | Donvito G et al. | β | 2019 | β |
| Emerging Therapeutic Role of PPAR-Ξ± in Cognition and Emotions. | Nisbett KE et al. | β | 2018 | β |
| Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia. | Perkins KA et al. | β | 2018 | β |
| Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study. | Ingrand I et al. | β | 2018 | β |
| Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver. | Ferguson LB et al. | β | 2018 | β |
| Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARΞ± agonist) in smokers. | Gendy MNS et al. | β | 2018 | β |
| Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels. | Rivera-Meza M et al. | β | 2017 | β |
| Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence? | Goodyear K et al. | β | 2017 | β |
| InΒ vivo interactions between Ξ±7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Ξ±: Implication for nicotine dependence. | Jackson A et al. | β | 2017 | β |
| Pioglitazone, a PPARΞ³ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. | Jones JD et al. | β | 2017 | β |
| The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats. | Haile CN et al. | β | 2017 | β |
| Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys. | Justinova Z et al. | β | 2016 | β |
| Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. | Ubaldi M et al. | β | 2016 | β |
| Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. | Perkins KA et al. | β | 2016 | β |
| Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. | Scherma M et al. | β | 2016 | β |
| Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research. | Henningfield JE et al. | β | 2016 | β |
| Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. | Justinova Z et al. | β | 2015 | β |
| Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications. | Stoker AK et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys. | Justinova Z et al. | β | 2015 | β |
| The Reinforcing Effects of Nicotine in Humans and Nonhuman Primates: A Review of Intravenous Self-Administration Evidence and Future Directions for Research. | Goodwin AK et al. | β | 2015 | β |
| Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. | Saha L et al. | β | 2014 | β |
| Effects of blockade of Ξ±4Ξ²2 and Ξ±7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats. | Liu X | β | 2014 | β |
| Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. | Robinson G et al. | β | 2014 | β |
| Opportunities for the development of neuroimmune therapies in addiction. | Ray LA et al. | β | 2014 | β |
| PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. | Ferguson LB et al. | β | 2014 | β |
| Role of cues and contexts on drug-seeking behaviour. | Perry CJ et al. | β | 2014 | β |
| Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives. | Melis M et al. | β | 2014 | β |
| The effects of lactation on impulsive behavior in vasopressin-deficient Brattleboro rats. | Aliczki M et al. | β | 2014 | β |
| Handling relapse in smoking cessation: strategies and recommendations. | Caponnetto P et al. | β | 2013 | β |
| Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. | Panlilio LV et al. | β | 2013 | β |
| Neuroimmune signaling: a key component of alcohol abuse. | Mayfield J et al. | β | 2013 | β |
| Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. | Le Foll B et al. | β | 2013 | β |
| PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. | Puligheddu M et al. | β | 2013 | β |
| PPARΞ± regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving Ξ±7 nicotinic acetylcholine receptors. | Melis M et al. | β | 2013 | β |
| Prior exposure to THC increases the addictive effects of nicotine in rats. | Panlilio LV et al. | β | 2013 | β |
| Stimulation of nicotine reward and central cholinergic activity in Sprague-Dawley rats exposed perinatally to a fat-rich diet. | Morganstern I et al. | β | 2013 | β |
| Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. | Harmey D et al. | β | 2012 | β |
| Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. | Melis M et al. | β | 2012 | β |